Humacyte Inc Revenue Growth Rates (HUMA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Humacyte Inc   (NASDAQ: HUMA)
 

HUMA's Revenue Growth by Quarter and Year

Humacyte Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/HUMA/growth
https://api.csimarket.com/api/v1/companies/HUMA/fundamentals
https://api.csimarket.com/api/v1/companies/HUMA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
HUMA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 7.39
2nd Quarter June -4.75
1st Quarter March 9.02
FY 11.66

HUMAs Annual Revenue
Humacyte Inc 's Revenue in the fiscal year 2025 $ 40.80 millions
Humacyte Inc 's Revenue in the fiscal year 2024 $ 3.92 millions
Humacyte Inc 's Revenue in the fiscal year 2023 $ -0.26 millions
Humacyte Inc 's Revenue in the fiscal year 2022 $ 1.57 millions
Humacyte Inc 's Revenue in the fiscal year 2021 $ 1.26 millions




HUMA Revenue third quarter 2026 Y/Y Growth Comment
Humacyte Inc reported Revenue rise of 55.27% year on year in the third quarter 2026, to $ 7.39 millions, this is lower than Humacyte Inc 's recent average Revenue surge of 1644.03%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 40 other companies have achieved higher Revenue growth. While Humacyte Inc ' s Revenue jump of 55.27% ranks overall at the positon no. 2663 in the third quarter 2026.


HUMA Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 55.27 %
2nd Quarter June -
1st Quarter March -41.62 %
FY   -

Financial Statements
Humacyte Inc 's third quarter 2026 Revenue $ 7.39 millions HUMA's Income Statement
Humacyte Inc 's third quarter 2025 Revenue $ 4.76 millions Quarterly HUMA's Income Statement


HUMA Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March -57.13 %
FY (Year on Year)   -


Back to HUMA Growth rate Comparisons >> Back to HUMA Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #41
Healthcare Sector #380
Overall #2663

Revenue Y/Y Growth Statistics
High Average Low
5499.51 % 1644.03 % 56.29 %
(Sep 30 2025)   (Jun 30 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #41
Healthcare Sector #380
Overall #2663
Revenue Y/Y Growth Statistics
High Average Low
5499.51 % 1644.03 % 56.29 %
(Sep 30 2025)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Humacyte Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


HUMA's III. Quarter Q/Q Revenue Comment
III. Quarter 2026Periodic Humacyte Inc in the circumstances of $ 7.39 millionsPeriodic circumstances have added to Humacyte Inc 's restoration of positive trends, as HUMA deliverRevenue of $ 7.39 millions in the III. Quarter 2026 emanate -4.75 millions in the second quarter. Humacyte Inc announced in the III. Quarter 2026 Revenue of $ 7.39 millions compare to recorded in previos quarter.

Within Biotechnology & Pharmaceuticals industry Humacyte Inc achieved highest sequential Revenue growth. While Humacyte Inc 's Revenue growth quarter on quarter, overall rank is .


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


HUMA's III. Quarter Q/Q Revenue Comment
III. Quarter 2026Periodic Humacyte Inc in the circumstances of $ 7.39 millionsPeriodic circumstances have added to Humacyte Inc 's restoration of positive trends, as HUMA deliverRevenue of $ 7.39 millions in the III. Quarter 2026 emanate -4.75 millions in the second quarter. Humacyte Inc announced in the III. Quarter 2026 Revenue of $ 7.39 millions compare to recorded in previos quarter.

Within Biotechnology & Pharmaceuticals industry Humacyte Inc achieved highest sequential Revenue growth. While Humacyte Inc 's Revenue growth quarter on quarter, overall rank is .


Humacyte Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 32.70
Y / Y Revenue Growth (TTM) 42.45 %
Year on Year Revenue Growth Overall Ranking # 9
Seqeuential Revenue Change (TTM) 8.74 %
Seq. Revenue Growth (TTM) Overall Ranking # 2663


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Humacyte Inc 's cumulative twelve months Revenue were $ 33 millions, company would post below average annual Revenue growth of 8.74% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Humacyte Inc 's Revenue growth from the -4.75% growth in Jun 30 2026.

Among companies within the Healthcare sector 3 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 7 to 9.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 41
Healthcare Sector # 4
Overall # 9

Revenue TTM Y/Y Growth Statistics
High Average Low
5499.51 %
 1644.03 %
56.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 41
Sector # 380
S&P 500 # 2663
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Humacyte Inc 's cumulative twelve months Revenue were $ 33 millions, company would post below average annual Revenue growth of 56.29% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Humacyte Inc 's Revenue growth from the -4.75% growth in Jun 30 2026.

Among companies within the Healthcare sector 3 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 7 to 9.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 41
Healthcare Sector # 4
Overall # 9

Revenue TTM Y/Y Growth Statistics
High Average Low
5499.51 %
1644.03 %
56.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 41
Sector # 380
S&P 500 # 2663




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
HUMA's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions


About Humacyte Inc Revenue Growth Rates (HUMA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Humacyte Inc (CIK 1818382).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-455588
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Humacyte Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.